Antiphospholipid Antibody (APLA) Syndrome presents diagnostic challenges and requires nuanced long-term management to prevent recurrent thrombosis. Chaired by Dr Tulika Seth, with panelists Dr Ranjan Gupta and Dr Abhay Bhave, this session will cover updated diagnostic criteria, clinical scenarios, and therapeutic strategies for this complex autoimmune-mediated prothrombotic disorder.

Navigating APLA Syndrome: From Diagnosis to Thrombosis Management

Review in Current Practice in Venous Thromboembolism is a two-day live virtual conference dedicated to advancing the understanding and management of VTE. Join leading experts as they explore emerging science, evolving risk stratification tools, and modern therapeutic strategies across diverse patient populations. This focused update on thrombosis care offers clinicians practical, evidence-based insights to improve outcomes across inpatient, outpatient, and high-risk settings.
Key Topics
Innovations in VTE: Advances in diagnostics, risk prediction, and the future of thrombosis care
Inpatient to Post-Discharge: Continuum of VTE prevention in hospitalized medical patients
Risk Stratification 2.0: Newer techniques using biomarkers & imaging advancements
Specialised care: including VTE management in women and the elderly
Procedural Interventions in DVT: What every physician should know about IVC filters and venous stents
Cancer-Associated Thrombosis: Personalized anticoagulation and new therapy frontiers
Managing APLA Syndrome: From diagnosis to long-term thrombosis prevention
This comprehensive review will help refine your clinical decision-making in VTE care. Stay updated, stay prepared-Register now to secure your spot.

RCP VTE Day 2

Accurate VTE risk assessment is critical, yet current tools have limitations in precision and accessibility. Under the chairmanship of Dr Abhay Bhave, with panelist Dr Velu Nair, this discussion will delve into the emerging role of biomarkers, advanced imaging modalities, and AI-driven models in transforming how clinicians predict and prevent VTE.

Revolutionizing VTE Risk Assessment: Biomarkers, Imaging, and AI Integration

RCP VTE Day 1

Join us for an insightful session on Myeloma: An Overview with renowned hematologist Dr. Abhay Bhave. With decades of experience in diagnosing and managing complex hematological disorders, Dr. Bhave will walk us through the evolving landscape of multiple myeloma — from clinical presentation and diagnostic challenges to the latest advancements in treatment. Whether you're a general physician or a specialist, this session offers a concise yet comprehensive understanding of this plasma cell malignancy. Don't miss this opportunity to enhance your approach to diagnosing and treating myeloma in clinical practice.

Myeloma: An Overview

Experience a crucial live session with Dr. Abhay Bhave and Lt Gen (Dr) Velu Nair on optimizing anticoagulant therapy. This session will cover effective strategies for educating patients on adherence, managing side effects, and implementing lifestyle changes. Learn best practices for monitoring therapy, including assessing renal function and managing drug interactions. Discover the value of a multidisciplinary approach, collaborating with specialists like oncologists and nephrologists for comprehensive care. Evaluate real-world case studies to tackle practical challenges and engage in interactive discussions to apply theoretical knowledge to improve quality in anticoagulation therapy.

Anticoagulation Stewardship: Best Practices for Optimal Patient Care

Participate in an insightful live session with Dr. Abhay Bhave and Dr. Tulika Seth on optimizing anticoagulant therapy. This session will compare the safety and efficacy of traditional anticoagulants (warfarin, heparin) with newer oral options (NOACs). We will review current guidelines from ACCP, ESC, ASH, NCCN, and NICE, and discuss recommendations for anticoagulant use in diverse patient groups, including those undergoing total hip or knee replacement for primary prophylaxis. Explore the impact of guideline-directed therapy on patient outcomes and clinical practice and evaluate how standardized protocols can enhance treatment consistency. Don’t miss this opportunity to refine your approach to anticoagulant management.

Current Practices in the Prophylaxis of VTE

Be a part of an essential live session with Dr. Tulika Seth and Dr. Abhay Bhave on VTE risk assessment and management. This session will cover the Caprini Risk Assessment Model’s key components and clinical applications, along with the Wells Score for Deep Vein Thrombosis (DVT) and the revised Geneva Score for Pulmonary Embolism (PE), including their uses and limitations. We’ll explore the PESI (Pulmonary Embolism Severity Index) for assessing PE severity, the Hestia Criteria for evaluating hospitalization needs in PE patients, and how to tailor risk assessment models for special populations such as the elderly, obese individuals, CKD or cancer patients, pregnant/post-partum women, and pediatric patients. Enhance your risk assessment skills.

Diagnosis and Risk Assessment in VTE

Join leading experts Dr. Alexander Cohen, Lt Gen (Dr) Velu Nair, Dr. Tulika Seth, and Dr. Abhay Bhave for a series of live sessions on Venous Thromboembolism (VTE). These sessions will delve into the incidence, prevalence, and risk factors of VTE, with a focus on diagnostic challenges and the impact on special populations. Explore the pathophysiology of VTE, compare traditional and modern anticoagulant therapies, and refine your risk assessment skills using key models like the Caprini, Wells, and Geneva Scores. Enhance your understanding and management of VTE to improve patient outcomes in clinical practice.

RCP - Venous Thromboembolism

Senior Consultant, Department of Haematology, Lilavati Hospital, Mumbai

The Review of Current Practices (RCP) on venous thromboembolism (VTE) kicks off with a focused and clinically rich Day 1, chaired by Lt Gen (Dr.) Velu Nair (Retd.). Designed for busy clinicians, the evening features 3 expert-led sessions that lay the foundation for evidence-based VTE management.

The agenda begins with an overview of contemporary approaches, followed by a discussion of thromboprophylaxis and risk stratification, emphasizing translation of evidence into real-world clinical decision-making. This is complemented by a session on catheter-related thrombosis, bringing in interventional and surgical perspectives.

The day culminates in an in-depth panel discussion, focusing on personalizing VTE management in complex “grey zone” populations, including obesity, bleeding risk, renal dysfunction, and young adults.

With interactive elements such as live polls, audience Q&A, and case-based insights, Day 1 sets the stage for a practical, nuanced understanding of VTE management. Participants will also engage through pre–post assessments, with certificates awarded upon completion.

RCP VTE 2026 - Day 1

This session explores the interventional and surgical dimensions of catheter-related thrombosis, a clinically significant yet often underrecognized complication. The session covers pathophysiology, diagnostic approach, and evidence-informed management strategies, offering perspectives on when to intervene surgically versus medically in patients with catheter-associated deep vein thrombosis.

Implementation of National VTE Preventive Strategies

An interactive panel discussion on personalizing VTE management in challenging patient populations. Led by Dr. Velu Nair, the session tackles clinical grey zones, including obesity, active bleeding risk, stroke prevention in atrial fibrillation (SPAF), renal failure, and VTE in young adults, providing nuanced, individualized approaches grounded in current evidence and real-world practice.

From Guidelines to Ground Reality: Personalizing VTE Management in the Grey Zone Population

Day 2 of the Review of Current Practices (RCP) on venous thromboembolism (VTE) builds on foundational concepts with a sharper focus on high-risk scenarios and evolving treatment paradigms. Chaired by Lt Gen (Dr.) Velu Nair (Retd.), the day features 4 expert-led sessions designed to refine clinical decision-making.

The evening begins with a recap of key Day 1 insights, followed by a keynote by Dr. Velu Nair on cancer-associated thrombosis, addressing treatment complexities in high-risk patients. Then presents emerging evidence in anticoagulation, with insights from the COBRRA trial and its clinical implications.

Subsequent sessions include rationalizing the use of DOACs, LMWH, and oral anticoagulants, and a discussion on selecting between interventional and medical management strategies in VTE.

The program concludes with closing remarks and key takeaways, reinforcing practical application. As with Day 1, the format remains highly interactive with live polls, audience engagement, and knowledge assessments, ensuring meaningful learning outcomes for participants.

RCP VTE 2026 - Day 2

This session includes a clinically focused debate on the evolving role of interventional strategies — including catheter-directed thrombolysis and surgical embolectomy — versus optimized medical therapy in the management of VTE. The session critically evaluates current evidence, patient selection criteria, risk-benefit considerations, and the growing armamentarium of endovascular options for pulmonary embolism and DVT.

Dr. Abhay Bhave

14

5.3k

262.5k

4.8

Upcoming Sessions

Sessions Taken

1.1k

4.7

844

4.8

1.2k

4.7

1k

4.7

1k

4.8

2.2k

0

2.2k

0

2.2k

0

2.2k

4.8